USPTO serial 79430064
BREATHING SCIENCE INTO LIFE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HARMON KENNEDY, HEATHER N
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with BREATHING SCIENCE INTO LIFE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in cell cultures, other than for medical or veterinary purposes, for boosting cells in the immune system for improved therapies; biological preparations for use in cell cultures, in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents in the nature of complexes of molecules for scientific research and for clinical and industrial use; proteins for use in scientific research; regulatory proteins in raw material for scientific research. | ACTIVE | — |
| 005 | Medical, biological, and pharmaceutical preparations for the treatment of pulmonary diseases; veterinary preparations for pulmonary diseases; medical, biological, and pharmaceutical preparations for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; veterinary preparations for pets, cattle, livestock for preventing and treating infectious diseases, medical disorders, and diseases, namely, lung cancer; medical, biological, and pharmaceutical preparations for preventing and treating viral, bacterial, and yeast infections; veterinary preparations for pets, cattle, livestock for preventing and treating viral, bacterial, and yeast infections; medical, biological, and pharmaceutical preparations for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines; regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes; pharmaceutical compounds being a component in pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the prevention of diseases of the respiratory system; diagnostic preparations for medical purposes; chemical diagnostic reagents for medical use. | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals; custom manufacture of pharmaceuticals, biopharmaceuticals and vaccines in relation to cell therapy, gene editing, protein replacement, and antibodies; provision of information, advice and consultancy services in the field of the aforesaid services. | ACTIVE | — |
| 042 | Biological research; clinical research in the field of respiratory diseases, pulmonary diseases, pulmonary surgery; medical research; research and development services in the field of pharmaceutical preparations; pharmaceutical products development; pharmaceutical product evaluation; research in the field of pharmaceuticals; testing of pharmaceuticals; pharmaceutical and medical research and development services in the field of various medical disorders, cancer, pulmonary diseases and infectious diseases; vaccine research and development services; research and development in the field of microorganisms and cells; development of gene-based medicines; drug discovery services; conducting clinical trials for pharmaceutical products for others; scientific laboratory services; laboratory research services relating to pharmaceuticals; consultation in the field of scientific risk assessment, namely, prediction and assessment of scientific risks to public and private agencies; consultancy in the field of pharmaceutical research; scientific research services in the nature of conducting clinical trials for others for assessing the efficiency of pharmaceuticals; chemical research and analysis services; medical research and development services in the field of respiratory diseases, pulmonary diseases, cancer; pharmacological research services; scientific research and development; scientific research in the field of respiratory diseases, pulmonary diseases, cancer for medical purposes; scientific research for medical purposes in the area of diseases; conducting clinical trials for others; scientific research in the field of genetics and genetic engineering; genetic research; genetic mapping for scientific purposes; DNA screening for scientific research purposes; DNA analysis services for scientific research purposes; providing scientific information in the field of medical disorders and their treatment; biotechnological research relating to enzymatic synthesis; technical research in the field of pharmaceutical studies; toxicity testing for scientific research purposes; toxicity analysis; information technology services in the nature of on-site management of information technology (IT) systems of others for the pharmaceutical and healthcare industries; conducting early evaluations in the field of new pharmaceuticals; providing scientific information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; design and development of computer software relating to the medical field; design and development of computer software relating to healthcare; veterinary research; provision of scientific information and data relating to medical and veterinary research and development. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PNEOO B.V.
- Other trademarks owned by PNEOO B.V.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named BREATHING SCIENCE INTO LIFE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 25, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 25, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 19, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 31, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 7, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 7, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 7, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 13, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 13, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 13, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 13, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 29, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 9, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 9, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 9, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 8, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2026 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Dec 2, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 1, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 25, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 14, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 15, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 15, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 14, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |